Skip to main content

Systemic Lupus Erythematosus

Immunology
131
Pipeline Programs
30
Companies
50
Clinical Trials
10 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
47
14
32
0
27
11
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4266%
Cell Therapy
1117%
Small Molecule
1016%
Peptide
12%
+ 163 programs with unclassified modality

Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.

$15.0B marketMature↑ Growing30 products15 companies

Key Trends

  • JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
  • Multiple patent cliffs emerging 2026-2028, creating generic competition risk
  • Robust pipeline with 4,996 trials signals continued innovation and market expansion

Career Verdict

Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1MOUNJAROGrowing
$2.4B
Eli Lilly and Company·PEAK15.6yr
#2SYMBICORTStable
$2.0B
AstraZeneca·LOE_APPROACHING
#3JAKAFIDeclining
$1.9B
Incyte·LOE_APPROACHING2.6yr
#4RESTASISStable
$1.5B
AbbVie·PEAK8.0yr
#5RINVOQGrowing
$976M
AbbVie·PEAK11.8yr

Drug Class Breakdown

Janus Kinase Inhibitors
$3.0B(20%)

dominant class with patent cliff risk

Corticosteroid Hormone Receptor Agonists
$2.8B(19%)

established, mature market segment

G-Protein-linked Receptor Interactions
$2.4B(16%)

driven by single blockbuster

Calcineurin Inhibitors
$1.6B(11%)

established immunosuppression class

Tumor Necrosis Factor Receptor Blocking Activity
$1.2B(8%)

legacy biologic class with competition

Career Outlook

Growing

Immunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.

Breaking In

Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.

For Experienced Professionals

Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.

In-Demand Skills

Medical Affairs and MSL expertise in immunosuppression and inflammatory diseasesJAK inhibitor mechanism expertise and competitive positioningClinical trial design and phase transition managementCommercial acumen for premium-priced biologics and small moleculesRegulatory strategy for label expansions and lifecycle management

Best For

Medical Science LiaisonBrand ManagerSenior Medical Affairs ManagerClinical Development ManagerCommercial Strategy Lead

Hiring Landscape

$212K-$387K

Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.

340
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

Johnson & Johnson
66Growing
Bristol Myers Squibb
50Growing
AbbVie
45Growing
argenx
31Growing
Sanofi
29Stable

By Department

Medical Affairs(32%)
$257K
Commercial(24%)
$270K
Research & Development(9%)
$387K
Clinical Operations(4%)
$345K
Manufacturing(2%)
$212K

Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.

On Market (2)

Approved therapies currently available

AstraZeneca
SAPHNELOApproved
anifrolumab-fnia
AstraZeneca
Type I Interferon Receptor Antagonist [EPC]injection2021
9M Part D
GSK
BENLYSTAApproved
belimumab
GSK
B Lymphocyte Stimulator-specific Inhibitor [EPC]injection2017

Competitive Landscape

77 companies ranked by most advanced pipeline stage

ViiV Healthcare
37 programs
11
6
6
5
BelimumabPhase 4Monoclonal Antibody
BelimumabPhase 4Monoclonal Antibody
Belimumab Injection [Benlysta]Phase 4
Belimumab plus Early VaccinationPhase 4
belimumabPhase 4Monoclonal Antibody
+32 more programs
GSK
GSKLONDON, United Kingdom
11 programs
1
BenlystaN/A1 trial
Cumulative corticosteroid exposureN/A1 trial
Scrutinizing the Heterogeneity of SLE: Defining PhenotypesN/A1 trial
GSK1550188 1mg/kg or 10mg/kgPHASE_11 trial
GSK2586184 standard formulationPHASE_11 trial
+6 more programs
Active Trials
NCT03370263Completed1,514Est. Sep 2025
NCT01616472Completed1Est. Jan 2016
NCT03348774Unknown950Est. Jul 2018
+8 more trials
Genome & Company
10 programs
1
3
4
1
Belimumab plus Early VaccinationPhase 41 trial
BelimumabPhase 3Monoclonal Antibody1 trial
BelimumabPhase 3Monoclonal Antibody1 trial
Belimumab 1 mg/kgPhase 31 trial
belimumabPhase 3Monoclonal Antibody1 trial
+5 more programs
Active Trials
NCT01914770Completed1,016Est. Nov 2010
NCT00657007Completed70Est. Mar 2003
NCT00583362Completed298Est. Feb 2016
+7 more trials
Human BioSciences
10 programs
1
3
4
1
Belimumab plus Early VaccinationPhase 4
BelimumabPhase 3Monoclonal Antibody
BelimumabPhase 3Monoclonal Antibody
Belimumab 1 mg/kgPhase 3
belimumabPhase 3Monoclonal Antibody
+5 more programs
UNION therapeutics
8 programs
4
2
1
Mycophenolate MofetilPhase 41 trial
CD19 CAR-T cell infusionPhase 1/2Cell Therapy1 trial
CD19 Universal CAR-γδ T CellsPhase 1/21 trial
A-319Phase 11 trial
ACT100 InjectionPhase 11 trial
+3 more programs
Active Trials
NCT02842814Completed333Est. Sep 2022
NCT06400537Recruiting25Est. Dec 2026
NCT07408908Not Yet Recruiting48Est. Oct 2027
+5 more trials
AstraZeneca
6 programs
1
3
1
1
SAPHNELO(anifrolumab)Phase 3Monoclonal Antibody5 trials
ICI 182,780Phase 2
MEDI-545Phase 21 trial
MEDI-546Phase 21 trial
AZD5492Phase 1
+1 more programs
Active Trials
NCT01031836Completed30Est. Jul 2016
NCT01559090Completed17Est. Feb 2017
NCT04750057No Longer Available
+4 more trials
Alliance Pharmaceuticals
3 programs
2
1
AtorvastatinPhase 4Small Molecule1 trial
Lisinopril PillsPhase 21 trial
transcutaneous vagus nerve stimulationPhase 21 trial
Active Trials
NCT04486118Active Not Recruiting36Est. Mar 2026
NCT06987565Not Yet Recruiting18Est. May 2027
NCT00120887Completed200Est. Dec 2005
Prevail Therapeutics
10 programs
1
3
6
BaricitinibPhase 3Small Molecule1 trial
BaricitinibPhase 3Small Molecule1 trial
BaricitinibPhase 3Small Molecule1 trial
LY2127399Phase 31 trial
LY2127399Phase 31 trial
+5 more programs
Active Trials
NCT03556007Completed48Est. Aug 2019
NCT02708095Completed314Est. Nov 2017
NCT05123586Terminated85Est. Dec 2023
+7 more trials
Sandoz
4 programs
1
3
IanalumabPhase 3Monoclonal Antibody1 trial
ianalumabPhase 3Monoclonal Antibody1 trial
switch to MyforticPhase 31 trial
YTB323Phase 1/21 trial
Active Trials
NCT05798117Active Not Recruiting21Est. Sep 2026
NCT05639114Active Not Recruiting436Est. Mar 2029
NCT05624749Active Not Recruiting288Est. Apr 2029
+1 more trials
Incyte
3 programs
3
BaricitinibPhase 3Small Molecule
BaricitinibPhase 3Small Molecule
BaricitinibPhase 3Small Molecule
Allergy Therapeutics
6 programs
1
1
ICI 182,780Phase 21 trial
atorvastatinPhase 1/2Small Molecule1 trial
Autoimmunity in Sisters of Lupus PatientsN/A1 trial
Peripheral lab drawsN/A1 trial
The Role of ITGAM in Systemic Lupus ErythematosusN/A1 trial
+1 more programs
Active Trials
NCT01076101Completed817Est. Dec 2016
NCT00519454Unknown75Est. Dec 2013
NCT01230112Completed40Est. Apr 2012
+4 more trials
Biocorp
6 programs
2
3
1
PRV-3279Phase 21 trial
CABA-201Phase 1/21 trial
CD19 CAR-T cell infusionPhase 1/2Cell Therapy
CD19 Universal CAR-γδ T CellsPhase 1/2
BudoprutugPhase 12 trials
+1 more programs
Active Trials
NCT07564596Not Yet Recruiting30Est. Sep 2027
NCT07011043Recruiting30Est. Apr 2027
NCT06121297Recruiting28Est. Dec 2029
+1 more trials
MSD
4 programs
2
1
MK-6194Phase 2
GardasilPhase 1
MK-1045Phase 1
GardasilN/A
Sharp Therapeutics
4 programs
2
1
MK-6194Phase 21 trial
GardasilPhase 11 trial
MK-1045Phase 12 trials
GardasilN/A1 trial
Active Trials
NCT00786409Completed27Est. Dec 2011
NCT01741012Completed37Est. Nov 2015
NCT07519772Not Yet Recruiting200Est. Oct 2030
+2 more trials
Amgen
AmgenTHOUSAND OAKS, CA
3 programs
2
1
DaxdilimabPhase 2Monoclonal Antibody1 trial
AMG 557Phase 11 trial
Efavaleukin AlfaPhase 15 trials
Active Trials
NCT00774943Completed58Est. May 2012
NCT05672199Terminated25Est. Oct 2024
NCT04987307Terminated221Est. Oct 2024
+4 more trials
Resolve Therapeutics
2 programs
1
1
RSLV-132Phase 21 trial
RSLV-132Phase 11 trial
Active Trials
NCT02194400Completed32Est. Nov 2015
NCT02660944Completed64Est. Aug 2020
Keymed Biosciences
2 programs
1
1
CM313 injectionPhase 21 trial
CM313 2 mg/kgPhase 1/21 trial
Active Trials
NCT05465707Unknown40Est. Oct 2023
NCT06791772Not Yet Recruiting150Est. Feb 2027
Neovacs
2 programs
1
1
IFNα-KinoidPhase 21 trial
IFN-KPhase 1/21 trial
Active Trials
NCT01058343Completed28Est. Jun 2016
NCT02665364Terminated185Est. Feb 2020
Innovation Pharmaceuticals
2 programs
1
1
Cenerimod 0.5 mgPhase 21 trial
Matching placeboPhase 1/21 trial
Active Trials
NCT02472795Completed105Est. Feb 2017
NCT03742037Completed427Est. Aug 2022
Corestemchemon
1 program
1
CS20AT04Phase 21 trial
Active Trials
NCT04835883Unknown10Est. Jan 2026
Iltoo Pharma
1 program
1
ILT-101Phase 21 trial
Active Trials
NCT02955615Completed100Est. Feb 2019
Active Biotech
1 program
1
paquinimodPhase 22 trials
Active Trials
NCT01487551Completed9Est. Feb 2013
NCT00997100Completed13Est. Sep 2010
Pfizer
PfizerNEW YORK, NY
4 programs
2
1
Arthritis Self Management ProgramPhase 1/21 trial
PF-06835375Phase 11 trial
TRU-015Phase 11 trial
Web-based Genetic Research on LupusN/A1 trial
Active Trials
NCT02530944Completed5,000Est. Oct 2017
NCT03334851Completed74Est. Feb 2022
NCT00479622Terminated20Est. May 2008
+1 more trials
Essen Biotech
1 program
1
CD19- BCMA CAR-T cellsPhase 1/2Cell Therapy1 trial
Active Trials
NCT06350110Recruiting75Est. Dec 2025
AbelZeta Pharma
1 program
1
CD20/BCMA-directed CAR-T cellsPhase 1/2Cell Therapy2 trials
Active Trials
NCT07341828Not Yet Recruiting15Est. Feb 2029
NCT06249438Recruiting30Est. Mar 2040
Lyell Immunopharma
1 program
1
IMPT-514Phase 1/21 trial
Active Trials
NCT06153095Withdrawn0Est. Jan 2025
BioTherapeutics Inc
3 programs
2
T cell injection targeting CD19 chimeric antigen receptorPhase 11 trial
UTAA91 injectionPhase 11 trial
T cell injection targeting CD19 chimeric antigen receptorN/A1 trial
Active Trials
NCT06361745Unknown10Est. Mar 2025
NCT06417398Unknown10Est. May 2025
NCT06970951Not Yet Recruiting15Est. Apr 2027
Cugene
2 programs
2
CUG252Phase 11 trial
CUG252Phase 11 trial
Active Trials
NCT05328557Completed32Est. Aug 2022
NCT05866861Active Not Recruiting40Est. Apr 2025
RemeGen
2 programs
2
TelitaciceptPhase 11 trial
TelitaciceptPhase 11 trial
Active Trials
NCT05247203Completed92Est. Nov 2023
NCT05687526Completed16Est. Nov 2025
Amoytop Biotech
1 program
1
ACT100 InjectionPhase 1

+47 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AstraZenecaanifrolumab
Bristol Myers SquibbDeucravacitinib
GSKBelimumab
Bristol Myers SquibbDeucravacitinib
UNION therapeuticsMycophenolate Mofetil
GSKBelimumab
GSKBelimumab
GSKBelimumab
Genome & CompanyBelimumab plus Early Vaccination
Alliance PharmaceuticalsAtorvastatin
AstraZenecaanifrolumab
Bristol Myers SquibbDeucravacitinib
GSKBelimumab
UCB PharmaDZP
Vor BiopharmaTelitacicept

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 20,037 patients across 50 trials

NCT06594068AstraZenecaanifrolumab

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Start: Jan 2026Est. completion: Aug 202716 patients
Phase 4Recruiting
NCT06476834Bristol Myers SquibbDeucravacitinib

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

Start: Jun 2024Est. completion: Nov 20248 patients
Phase 4Completed
NCT06411249GSKBelimumab

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Start: Jun 2024Est. completion: May 2029350 patients
Phase 4Recruiting
NCT05858645Bristol Myers SquibbDeucravacitinib

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Start: Oct 2023Est. completion: Jun 202625 patients
Phase 4Recruiting
NCT05916781UNION therapeuticsMycophenolate Mofetil

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

Start: Jul 2023Est. completion: Jul 2026220 patients
Phase 4Recruiting
NCT04447053GSKBelimumab

Sequential Belimumab and T-cell Based Therapy in SLE

Start: Nov 2021Est. completion: May 202580 patients
Phase 4Unknown
NCT04908865GSKBelimumab

Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

Start: Oct 2021Est. completion: Aug 202467 patients
Phase 4Completed
NCT02270970GSKBelimumab

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

Start: Oct 2014Est. completion: Dec 201920 patients
Phase 4Unknown
NCT01597492Genome & CompanyBelimumab plus Early Vaccination

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Start: May 2012Est. completion: Sep 201579 patients
Phase 4Completed
NCT00120887Alliance PharmaceuticalsAtorvastatin

Lupus Atherosclerosis Prevention Study

Start: Apr 2002Est. completion: Dec 2005200 patients
Phase 4Completed
NCT07430306AstraZenecaanifrolumab

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

Start: Apr 2026Est. completion: Jan 2029245 patients
Phase 3Not Yet Recruiting
NCT07116967Bristol Myers SquibbDeucravacitinib

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Start: Sep 2025Est. completion: Jan 20313,040 patients
Phase 3Recruiting
NCT06716606GSKBelimumab

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

Start: Dec 2024Est. completion: Dec 2029514 patients
Phase 3Recruiting
NCT06617325UCB PharmaDZP

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Start: Nov 2024Est. completion: May 2028450 patients
Phase 3Recruiting
NCT06456567Vor BiopharmaTelitacicept

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Start: Sep 2024Est. completion: Jan 20250
Phase 3Withdrawn
NCT05624749Sandozianalumab

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

Start: Apr 2023Est. completion: Apr 2029288 patients
Phase 3Active Not Recruiting
NCT05639114SandozIanalumab

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Start: Mar 2023Est. completion: Mar 2029436 patients
Phase 3Active Not Recruiting
NCT05620407Bristol Myers SquibbDeucravacitinib

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

Start: Jan 2023Est. completion: Nov 2028513 patients
Phase 3Active Not Recruiting
NCT05306574Vor BiopharmaTelitacicept

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Start: Jun 2022Est. completion: Jan 202591 patients
Phase 3Terminated
NCT04976322UCB PharmaDapirolizumab pegol

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Start: Jul 2021Est. completion: Aug 2030760 patients
Phase 3Enrolling By Invitation
NCT04294667UCB PharmaDZP

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Start: Aug 2020Est. completion: Jun 2024321 patients
Phase 3Completed
NCT03843125Prevail TherapeuticsBaricitinib

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

Start: Sep 2019Est. completion: Apr 20221,147 patients
Phase 3Terminated
NCT03747159GSKBelimumab

Synergetic B-cell Immunomodulation in SLE - 2nd Study.

Start: Oct 2018Est. completion: Jun 202670 patients
Phase 3Active Not Recruiting
NCT03616912Prevail TherapeuticsBaricitinib

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

Start: Aug 2018Est. completion: Mar 2022830 patients
Phase 3Terminated
NCT03616964Prevail TherapeuticsBaricitinib

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

Start: Aug 2018Est. completion: Oct 2021778 patients
Phase 3Completed
NCT02119156GSKBelimumab

Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

Start: May 2014Est. completion: Dec 201880 patients
Phase 3Completed
NCT01597622Genome & CompanyBelimumab

BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115

Start: Jun 2012Est. completion: Sep 2018142 patients
Phase 3Completed
NCT01488708Prevail TherapeuticsLY2127399

On Open-Label Study in Participants With Systemic Lupus Erythematosus

Start: Jan 2012Est. completion: Oct 20151,518 patients
Phase 3Terminated
NCT01408576UCB PharmaEpratuzumab

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

Start: Jul 2011Est. completion: Feb 20161,250 patients
Phase 3Completed
NCT01345253Genome & CompanyBelimumab

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

Start: May 2011Est. completion: Sep 2018709 patients
Phase 3Completed
NCT01205438Prevail TherapeuticsLY2127399

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Start: Jan 2011Est. completion: Mar 20151,124 patients
Phase 3Completed
NCT01240694TevaCEP-33457

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

Start: Dec 2010Est. completion: Jun 2012136 patients
Phase 3Terminated
NCT01196091Prevail TherapeuticsLY2127399

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Start: Dec 2010Est. completion: Jun 20151,164 patients
Phase 3Completed
NCT01262365UCB PharmaEpratuzumab

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Start: Dec 2010Est. completion: May 2015793 patients
Phase 3Completed
NCT00724867Genome & CompanyBelimumab 1 mg/kg

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

Start: Aug 2008Est. completion: Mar 2015268 patients
Phase 3Completed
NCT00712933Genome & Companybelimumab

A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

Start: May 2008Est. completion: Dec 2016738 patients
Phase 3Completed
NCT00504244Sandozswitch to Myfortic

Myfortic Versus Azathioprine in Systemic Lupus Erythematosus

Start: Jul 2007Est. completion: Aug 200912 patients
Phase 3Terminated
NCT00382837UCB PharmaEpratuzumab

Study of Epratuzumab in Systemic Lupus Erythematosus

Start: Jan 20070
Phase 3Withdrawn
NCT00111306UCB Pharmaepratuzumab

Study of Epratuzumab in Systemic Lupus Erythematosus

Start: Jun 2005Est. completion: Mar 2007510 patients
Phase 3Terminated
NCT00383214UCB PharmaEpratuzumab

Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Start: May 2005Est. completion: Mar 200754 patients
Phase 3Terminated
NCT07409181Boehringer IngelheimBI 3000202

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Start: Apr 2026Est. completion: Jun 2029405 patients
Phase 2Recruiting
NCT07508488Bristol Myers SquibbDeucravacitinib

Deucravacitinib in the Treatment of Cicatricial Alopecias

Start: Apr 2026Est. completion: Jan 202720 patients
Phase 2Not Yet Recruiting
NCT07539857GSKBelimumab

Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized

Start: Apr 2026Est. completion: Jan 203025 patients
Phase 2Not Yet Recruiting
NCT06987565Alliance Pharmaceuticalstranscutaneous vagus nerve stimulation

Transcutaneous Vagus Nerve Stimulation in SLE

Start: May 2025Est. completion: May 202718 patients
Phase 2Not Yet Recruiting
NCT06725264Bristol Myers SquibbDeucravacitinib

Tyrosine Kinase 2 (TYK2) for GA and CS

Start: Mar 2025Est. completion: Jun 20260
Phase 2Withdrawn
NCT06859931Chia Tai TianQing Pharmaceutical GroupTQB3702 Tablets

Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

Start: Mar 2025Est. completion: Dec 2026120 patients
Phase 2Not Yet Recruiting
NCT06791772Keymed BiosciencesCM313 injection

Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)

Start: Feb 2025Est. completion: Feb 2027150 patients
Phase 2Not Yet Recruiting
NCT06381453GSKBelimumab

Belimumab in Autoimmune Hepatitis

Start: Dec 2024Est. completion: Apr 202948 patients
Phase 2Recruiting
NCT06559163Zenas BioPharmaObexelimab

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

Start: Sep 2024Est. completion: Sep 2026190 patients
Phase 2Recruiting
NCT06374212AstraZenecaanifrolumab

Anifrolumab for Hidradenitis Suppurativa

Start: Jun 2024Est. completion: Apr 202615 patients
Phase 2Active Not Recruiting

Related Jobs in Immunology

Senior Manager, Total Rewards

Tonix PharmaceuticalsTonix Pharmaceuticals
Berkeley Heights, NJ
Yesterday
$130K - $170K/yr

Associate Director, CMC Lead, Late-Stage Biologics

Oruka TherapeuticsOruka Therapeutics
Remote
Yesterday
$182K - $208K/yr

Senior Manager, Regulatory Affairs CMC

Spyre TherapeuticsSpyre Therapeutics
Remote
Yesterday
$150K - $176K/yr

Vice President, Biology and Translational Science

Apriori BioApriori Bio
Cambridge, MA USA
Yesterday
$275K - $340K/yr

Vice President, Biology and Translational Science

Prologue MedicinesPrologue Medicines
Cambridge, MA USA
Yesterday
$275K - $340K/yr

Vice President, Biology and Translational Science

Metaphore BiotechnologiesMetaphore Biotechnologies
Cambridge, MA USA
Yesterday
$275K - $340K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

27 late-stage (Phase 3) programs, potential near-term approvals
10 actively recruiting trials targeting 20,037 patients
30 companies competing in this space

Related Indications

Rheumatoid Arthritis(851)Atopic Dermatitis(457)Psoriasis(421)Ulcerative Colitis(274)Crohn's Disease(264)Arthritis, Rheumatoid(209)Plaque Psoriasis(140)Crohn Disease(89)Psoriasis Vulgaris(82)Ankylosing Spondylitis(76)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.